MR imaging of the effects of methylphenidate on brain structure and function in Attention-Deficit/Hyperactivity Disorder

European Neuropsychopharmacology

Volumn 23, Issue 10, 2013, Pages 1151-1164

  Schweren, Lizanne J S ^a   de Zeeuw, Patrick ^a   Durston, Sarah ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Childhood ADHD; Functional MRI; Methylphenidate; Structural MRI

Indexed keywords

METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ANTERIOR CINGULATE; ATTENTION; ATTENTION DEFICIT DISORDER; BRAIN; BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN SIZE; CEREBELLUM; CHILD; CHILD BEHAVIOR; COGNITION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HUMAN; HYPERACTIVITY; LONG TERM CARE; NEUROCHEMISTRY; NEUROIMAGING; PRIORITY JOURNAL; REVIEW; SYMPTOM; THALAMUS; TREATMENT RESPONSE; VOXEL BASED MORPHOMETRY; WHITE MATTER;

CHILDHOOD ADHD; FUNCTIONAL MRI; METHYLPHENIDATE; STRUCTURAL MRI;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADOLESCENT DEVELOPMENT; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD BEHAVIOR; CHILD DEVELOPMENT; DOPAMINE UPTAKE INHIBITORS; FUNCTIONAL NEUROIMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; METHYLPHENIDATE; NEUROGENESIS; NEURONS;

EID: 84884289152     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.10.014     Document Type: Review

References (73)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Ed. DSM-IV-TR (Text Revision). Washington DC: Author 2000.
2. Andersen S.L. Stimulants and the developing brain. Trends Pharmacol. Sci. 2005, 26(5):237-243.
3. Anderson C.M., Polcari A., Lowen S.B., Renshaw P.F., Teicher M.H. Effects of methylphenidate on functional magnetic resonance relaxometry of the cerebellar vermis in boys with ADHD. Am. J. Psychiatry 2002, 159(8):1322-1328.
4. Arnsten A.F.T. Stimulants: therapeutic actions in ADHD. Neuropharmacology 2006, 31:2376-2383.
5. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11(6 pt. 1):805-821.
6. Barbaresi W.J., Katusic S.K., Colligan R.C., Weaver A.L., Leibson C.L., Jacobsen S.J. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J. Dev. Behav. Pediatr. 2006, 27(1):1-10.
7. Batty M.J., Liddle E.B., Pitiot A., Toro R., Groom M.J., Scerif G., Liotti M., Liddle P.F., Paus T., Hollis C. Cortical gray matter in attention-deficit/hyperactivity disorder: a structural magnetic resonance imaging study. J. Am. Acad. Child Adolesc. Psychiatry 2010, 49(3):229-238.
8. Bédard A.C., Schulz K.P., Cook E.H., Fan J., Clerkin S.M., Ivanov I., Halperin J.M., Newcorn J.H. Dopamine transporter gene variation modulates activation of striatum in youth with ADHD. Neuroimage 2010, 53(3):935-942.
9. Bledsoe J., Semrud-Clikeman M., Pliszka S.R. A magnetic resonance imaging study of the cerebellar vermis in chronically treated and treatment-naïve children with attention-deficit/hyperactivity disorder combined type. Biol. Psychiatry 2009, 65(7):620-624.
10. Bussing R., Grudnik J., Mason D., Wasiak M., Leonard C. ADHD and conduct disorder: an MRI study in a community sample. World J. Biol. Psychiatry 2002, 3(4):216-220.
11. Canese R., Adriani W., Marco E.M., De Pasquale F., Lorenzini P., De Luca N., Fabi F., Podo F., Laviola G. Peculiar response to methylphenidate in adolescent compared to adult rats: a phMRI study. Psychopharmacology (Berlin) 2009, 203(1):143-153.
12. Carmona S., Vilarroya O., Bielsa A., Trèmols V., Soliva J.C., Rovira M., Tomàs J., Raheb C., Gispert J.D., Batlle S., Bulbena A. Global and regional gray matter reductions in ADHD: a voxel-based morphometric study. Neurosci. Lett. 2005, 389(2):88-93.
13. Castellanos F.X., Lee P.P., Sharp W., Jeffries N.O., Greenstein D.K., Clasen L.S., Blumenthal J.D., James R.S., Ebens C.L., Walter J.M., Zijdenbos A., Evans A.C., Giedd J.N., Rapoport J.L. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. J. Am. Med. Assoc. 2002, 288(14):1740-1748.
14. Conners C.K. Forty years of methylphenidate treatment in attention deficit/hyperactive disorder. J. Atten. Disord. 2002, 6:S17-S30.
15. Del Campo N., Chamberlain S.R., Sahakian B.J., Robbins T.W. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol. Psychiatry 2011, 69(12):e145-e157.
16. Depue B.E., Burgess G.C., Willcutt E.G., Bidwell L.C., Ruzic L., Banich M.T. Symptom-correlated brain regions in young adults with combined-type ADHD: their organization, variability, and relation to behavioural performance. Psychiatry Res. 2010, 182(2):96-102.
17. De Zeeuw P., Mandl R.C.W., Hulshoff H.E., van Engeland H., Durston S. Decreased frontostriatal microstructural organization in attention deficit/hyperactivity disorder. Hum. Brain Mapp. 2012, 33 (8), 1941-1951.
18. Dodds C.M., Müller U., Clark.L., van Loon A., Cools R., Robbins T.W. Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning. J Neurosci. 2008, 28(23):5976-5982.
19. Doyle A.E., Willcutt E.G., Seidman L.J., Biederman J., Chouinard V.A., Silva J., Faraone S.V. Attention-deficit/hyperactivity disorder endophenotypes. Biol. Psychiatry 2005, 57(11):1324-1335.
20. Durston S., Fossella J.A., Mulder M.J., Casey B.J., Ziermans T.B., Vessaz M.N., Van Engeland H. Dopamine transporter genotype conveys familial risk of attention-deficit/hyperactivity disorder through striatal activation. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47(1):61-67.
21. Durston S., de Zeeuw P., Staal W.G. Imaging genetics in ADHD: a focus on cognitive control. Neurosci. Biobehav. Rev. 2009, 33(5):674-689.
22. Dwan K., Altman D.G., Arnaiz J.A., Bloom J., Chan A.W., Cronin E., Decullier E., Easterbrook P.J., Von Elm E., Gamble C., Ghersi D., Ionnidis J.P., Simes J., Williamson P.R. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 2008, 3(8):e3081.
23. Epstein J.N., Casey B.J., Tonev S.T., Davidson M.C., Reiss A.L., Garrett A., Hinshaw S.P., Greenhill L.L., Glover G., Shafritz K.M., Vitolo A., Kotler L.A., Jarrett M.A., Spicer J. ADHD- and medication-related brain activation effects in concordantly affected parent-child dyads with ADHD. J. Child Psychol. Psychiatry 2007, 48(9):899-913.
24. Fusar-Poli P., Rubia K., Rossi G., Sartori G., Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am. J. Psychiatry 2012, 169 (3), 264-272.
25. Greenhill L.L., Findling R.L., Swanson J.M. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002, 109:E39.
26. Heal D.J., Cheetham S.C., Smith S.L. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009, 57:608-618.
27. Heinz A., Goldman D., Jones D.W., Palmour R., Hommer D., Gorey J.G., Lee K.S., Linnoila M., Weinberger D.R. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000, 22(2):133-139.
28. Honey G., Bullmore E. Human pharmacological MRI. Trends Pharmacol. Sci. 2004, 25(7):366-374.
29. Ivanov I., Bansal R., Hao X., Zhu H., Kellendonk C., Miller L., Sanchez-Pena J., Miller A.M., Chakravarty M.M., Klahr K., Durkin K., Greenhill L., Peterson B.S. Morphological abnormalities of the thalamus in youths with attention deficit hyperactivity disorder. Am. J. Psychiatry 2010, 167(4):397-408.
30. Kobel M., Bechtel N., Weber P., Specht K., Klarhöfer M., Scheffler K., Opwis K., Penner I.K. Effects of methylphenidate on working memory in children with attention deficit/hyperactivity disorder. Eur. J. Paediatr. Neurol. 2009, 13:516-523.
31. Konrad K., Neufang S., Fink G.R., Herpertz-Dahlmann B. Long-term effects of methylphenidate on neural networks associated with executive attention in children with ADHD: results from a longitudinal functional MRI study. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46(12):1633-1641.
32. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 1997, 68(5):2032-2037.
33. Lee Y.S., Han D.H., Lee J.H., Choi T.Y. The effects of methylphenidate on neural substrates associated with interference suppression in children with ADHD: a preliminary study using event related fMRI. Psychiatry Invest. 2010, 7(1):49-54.
34. Loo S.K., Specter E., Smolen A., Hopfer C., Teale P.D., Reite M.L. Functional effects of DAT1 polymorphism on EEG measures in ADHD. J. Am. Acad. Child Adolesc. Psychiatry 2003, 42(8):986-993.
35. Ludolph A.G., Kassubek J., Schmeck K., Glaser C., Wunderlich A., Buck A.K., Reske S.N., Fegert J.M., Mottaghy F.M. Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18 F]fluorophenyl-l-alanine PET study. NeuroImage 2008, 41(3):718-727.
36. McGauran N., Wieseler B., Kreis J., Schüler Y.B., Kölsch H., Kaiser T. Reporting bias in medical research-a narrative review. Trials 2010, 11:37.
37. Meijer W.M., Faber A., van den Ban E., Tobi H. Current issues around the pharmacotherapy of ADHD in children and adults. Pharm. World Sci. 2009, 31(5):509-516.
38. Minzenberg M.J. Pharmacological MRI approaches to understanding mechanisms of drug action. Curr. Topics. Behav. Neurosci. 2012, 11, 365-388.
39. MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch. Gen. Psychiatry 1999, 56(12):1073-1086.
40. Nakao T., Radua J., Rubia K., Mataix-Cols D. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am. J. Psychiatry 2011, 168(11):1154-1163.
41. Peterson B.S., Potenza M.N., Wang Z., Zhu H., Martin A., Marsh R., Plessen K.J., Yu S. An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am. J. Psychiatry 2009, 166(11):1286-1294.
42. Pliszka S.R. Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am. 2000, 9(3):525-540VII.
43. Pliszka S.R., Glahn D.C., Semrud-Clikeman M., Franklin C., Perez R., Xiong J., Liotti M. Neuroimaging of inhibitory control areas in children with attention deficit hyperactivity disorder who were treatment naive or in long-term treatment. Am. J. Psychiatry 2006, 163(6):1052-1060.
44. Plomp E., Van Engeland H., Durston S. Understanding genes, environment and their interaction in attention-deficit hyperactivity disorder: is there a role for neuroimaging?. Neuroscience 2009, 164(1):230-240.
45. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 2007, 164(6):942-948.
46. Prehn-Kristensen A., Krauel K., Hinrichs H., Fisher J., Malecki U., Schuetze H., Wolff S., Jansen O. Methylphenidate does not improve interference control during working memory in young patients with attention-deficit hyperactivity disorder. Brain Res. 2011, 1388:56-68.
47. Rapoport J.L., Gogtay N. Brain neuroplasticity in healthy, hyperactive and psychotic children: insights from neuroimaging. Neuropsychopharmacology 2008, 33(1):181-197.
48. Robinson T.E., Kolb B. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 2004, 47(Suppl. 1):33-46.
49. Rohde L.A., Roman T., Szobot C., Cunha R.D., Hutz M.H., Biederman J. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study. Synapse 2003, 48(2):87-89.
50. Rubia K., Halari R., Cubillo A., Mohammad A.M., Brammer M., Taylor E. Methylphenidate normalizes activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task. Neuropharmacology 2009, 57(7-8):640-652.
51. Rubia K., Halari R., Cubillo A., Smith A.B., Mohammad A.M., Brammer M., Taylor E. Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naïve boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology 2011, 36(8):1575-1586.
52. Rubia K., Halari R., Mohammad A.M., Taylor E., Brammer M. Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder. Biol. Psychiatry 2011, 70(3):255-262.
53. Schlochtermeier L., Stoy M., Schlagenhauf F., Wrase J., Park S.Q., Friedel E., Huss M., Lehmkuhl U., Heinz A., Ströhle A. Childhood methylphenidate treatment of ADHD and response to affective stimuli. Eur. Neuropsychopharmacol. 2011, 21(8):646-654.
54. Seidman L.J., Valera E.M., Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005, 57(11):1263-1272.
55. Semrud-Clikeman M., Pliszka S.R., Lancaster J., Liotti M. Volumetric MRI differences in treatment-naïve vs chronically treated children with ADHD. Neurology 2006, 67(6):1023-1027.
56. Shafritz K.M., Marchione K.E., Gore J.C., Shaywitz S.E., Shaywitz B.A. The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. Am. J. Psychiatry 2004, 161(11):1990-1997.
57. Shaw P., Sharp W., Morrison M., Eckstrand K., Greenstein D.K., Clasen L.S., Evans A.C., Rapoport J.L. Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder. Am. J. Psychiatry 2009, 166(1):58-63.
58. Sheridan M.A., Hinshaw S., D'Esposito M. Stimulant medication and prefrontal functional connectivity during working memory in ADHD: a preliminary report. J. Atten. Disord. 2010, 14(1):69-78.
59. Simon V., Czobor P., Bálint S., Mészáros A., Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br. J. Psychiatry 2009, 194(3):204-211.
60. Spencer T., Biederman J., Wilens T., Harding M., O'Donnell D., Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry 1996, 35(4):409-432.
61. Stoy M., Schlagenhauf F., Schlochtermeier L., Wrase J., Knutson B., Lehmkuhl U., Huss M., Heinz A., Ströhle A. Reward processing in male adults with childhood ADHD-a comparison between drug-naïve and methylphenidate-treated subjects. Psychopharmacology 2011, 215(3):467-481.
62. Swanson J.M., McBurnett K., Wigal T., Pfiffner L.J., Lerner M.A., Williams L., Christian D., Tamm L., Willcutt E., Crowley K., Clevenger W., Khouzam N., Woo C., Crinella F.M., Fisher T.D. Effect of stimulant medication on children with attention deficit disorder: a "review of reviews". Except. Child. 1993, 60:154-162.
63. Teicher M.H., Anderson C.M., Polcari A., Glod C.A., Maas L.C., Renshaw P.F. Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat. Med. 2000, 6(4):470-473.
64. Tomasi D., Volkow N.D., Wang G.J., Wang R., Telang F., Caparelli E.C., Wong C., Jayne M., Fowler J.S. Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls. Neuroimage 2011, 54(4):3101-3110.
65. Vaidya C.J., Austin G., Kirkorian G., Ridlehuber H.W., Desmond J.E., Glover G.H., Gabrieli J.D. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc. Natl. Acad. Sci. USA 1998, 95(24):14494-14499.
66. Valera E.M., Faraone S.V., Murray K.E., Seidman L.J. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol. Psychiatry 2007, 61(12):1361-1369.
67. Volkow N.D., Wang G., Fowler J.S., Logan J., Gerasimov M., Maynard L., Ding Y., Gatley S.J., Gifford A., Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 2001, 21(2):RC121.
68. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Angrist B., Hitzemann R., Lieberman J., Pappas N. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am. J. Psychiatry 1997, 154(1):50-55.
69. Wilens T.E., McBurnett K., Bukstein O., McGough J., Greenhill L., Lerner M., Stein M.A., Conners C.K., Duby J., Newcorn J., Bailey C.E., Kratochvil C.J., Coury D., Casat C., Denisco M.J., Halstead P., Bloom L., Zimmerman B.A., Gu J., Cooper K.M., Lynch J.M. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch. Pediatr. Adolesc. Med. 2006, 160:82-90.
70. Winstanley C.A., Eagle D.M., Robbins T.W. Behavioural models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clin. Psychol. Rev. 2006, 26(4):379-395.
71. Wong C.G., Stevens M.C. The effects of stimulant medication on working memory functional connectivity in attention-deficit/hyperactivity disorder. Biol. Psychiatry 2012, 71(5):458-466.
72. Wood A.C., Neale M.C. Twin studies and their implications for molecular genetic studies: endophenotypes integrate quantitative and molecular genetics in ADHD research. J. Am. Acad. Child. Adolesc. Psychiatry 2010, 49(9):874-883.
73. Zang Y.F., Jin Z., Weng X.C., Zhang L., Zeng Y.W., Yang L., Wang Y.F., Seidman L.J., Faraone S.V. Functional MRI in attention-deficit hyperactivity disorder: evidence for hypofrontality. Brain Dev. 2005, 27(8):544-550.